Dec. 09, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT recently announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.

AI Impacts Precision Oncology

Genomics has guided personalized cancer treatments for the past two decades. Now, AI biomarkers are expanding the field, helping radiologists and radiation oncologists stratify risk and potentially plan more precise treatments.

Unlike traditional biomarkers, “AI analyzes images of a patient’s biopsy to predict how aggressive a patient’s cancer might be, or whether they may respond better to treatment A or treatment B,” says Erin Stewart, vice president of clinical development for Artera, a developer of multimodal AI (MMAI)-based prognostic and predictive cancer tests.

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for Lunit INSIGHT Risk, a mammography-based five-year breast cancer risk prediction model. Potential clearance is expected in 2026.

A new study shows large increases in the use of computed tomography (CT) scans of the head in emergency departments across the United States from 2007 to 2022. The study, which was published on Nov.19, 2025, in Neurology, the medical journal of the American Academy of Neurology, also found disparities in use of head CTs by race, type of insurance and hospital location.

Dec. 1, 2025 — Rapid AI has released the inaugural episode of its original podcast, "Radiology Rewired."

The podcast tackles the topics that are shaping today’s radiology industry, from AI innovation and integration to workforce training and challenges, with interviews from some of the industry’s leading innovators and practitioners, like:

Figure 1

Healthcare has reached a critical juncture. The World Economic Forum estimates that global medical costs will see double digit increases for the third consecutive year since 2023, with estimates suggesting an average rise of 10.4 percent worldwide in 20251 driven by factors including overwhelmed public healthcare systems and a rising demand for private healthcare.

Nov. 30, 2025 — Fujifilm Healthcare Americas Corp. has launched Synapse One, a comprehensive, tailor-made workflow solution designed for outpatient imaging needs, in North America*.

Dec,. 1, 2025 — Canon has announced that the U.S. Food and Drug Administration (FDA) has granted [510(k) clearance/PMA approval] for its Alphenix 4D CT with Aquilion ONE/INSIGHT Edition, which follows a successful European launch in August. This next-generation Angio-CT hybrid one-suite solution (Alphenix 4D CT) represents Canon’s commitment to advancing interventional therapy with enhanced clinical workflows.

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end-to-end suite of modular, interoperable AI-powered applications that address real-world clinical needs across the breast cancer screening and detection pathways. Breast Suite builds on organic innovation and integrated technologies from iCAD to deliver a comprehensive suite of solutions.

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for treating patients with locally recurrent prostate cancer using the Company’s Alpha DaRT technology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now